Retour sur lavenir.net
   SOLVAY 27.660 € (+1,24 %)     UCB 226.200 € (-0,66 %)     KBC ANCORA 77.700 € (-0,38 %)     TUBIZE-FIN 191.500 € (-2,15 %)     SHURGARD 25.900 € (-2,08 %)     ENERGYVISION 12.800 € (0,00 %)     NYXOAH 2.500 € (-3,29 %)     LOTUS BAKERIES 10 140.000 € (+0,40 %)     D'IETEREN GROUP 174.800 € (-0,96 %)     ARGENX SE 656.000 € (-1,44 %)     WDP 23.200 € (-2,77 %)     ASCENCIO 49.500 € (-0,60 %)     EVS BROADC.EQUIPM. 36.900 € (+2,36 %)     PROXIMUS 6.480 € (-0,92 %)     BANQUP GROUP 2.500 € (-0,40 %)     DECEUNINCK 2.155 € (+0,23 %)     NYRSTAR 0.080 € (-2,20 %)     HYBRID SOFTWARE GR 3.980 € (0,00 %)     HOME INVEST BE. 19.300 € (-0,31 %)     BREDERODE 102.400 € (-0,39 %)     BEKAERT 41.600 € (-0,12 %)     VAN DE VELDE 32.600 € (0,00 %)     MELEXIS 67.500 € (-3,36 %)     VGP 87.100 € (-1,91 %)     AGEAS 66.550 € (-1,33 %)     WERELDHAVE BELGIUM 52.600 € (-0,38 %)     MATERIALISE 4.560 € (-1,72 %)     IBA 13.440 € (-0,88 %)     SIPEF 99.300 € (-0,70 %)     TINC 11.940 € (+0,34 %)     CIE BOIS SAUVAGE 324.000 € (-0,31 %)     FAGRON 24.000 € (+1,05 %)     AGFA-GEVAERT 0.480 € (+0,95 %)     CAMPINE 215.000 € (0,00 %)     COLRUYT 33.000 € (-0,42 %)     ACKERMANS V.HAAREN 275.400 € (-0,29 %)     DEME GROUP 186.800 € (0,00 %)     AEDIFICA 71.150 € (-2,27 %)     SOFINA 215.800 € (-1,01 %)     KINEPOLIS GROUP 30.650 € (-0,81 %)     UMICORE 17.070 € (-0,76 %)     CARE PROPERTY INV. 12.820 € (-0,47 %)     MONTEA 69.600 € (-1,42 %)     BPOST 1.784 € (-2,51 %)     ONWARD MEDICAL 2.650 € (-6,03 %)     AZELIS GROUP 11.070 € (-2,12 %)     BIOSENIC 0.002 € (-8,33 %)     TESSENDERLO 21.500 € (+0,23 %)     TITAN S.A. 45.900 € (-0,04 %)     VIOHALCO 14.900 € (+0,68 %)     RECTICEL 9.940 € (0,00 %)     RETAIL ESTATES 67.200 € (-2,18 %)     VASTNED 29.650 € (-0,34 %)     CMB.TECH 11.380 € (+0,71 %)     NEXTENSA 46.750 € (+0,43 %)     GBL 78.850 € (-1,00 %)     SYENSQO 55.500 € (+0,45 %)     JENSEN-GROUP 69.000 € (-1,71 %)     AB INBEV 62.600 € (-1,94 %)     IMMOBEL 20.900 € (+0,48 %)  
   EXOSENS 62.800 € (-1,95 %)     MICHELIN 31.150 € (-1,05 %)     ESSILORLUXOTTICA 180.600 € (-1,15 %)     HF COMPANY 4.930 € (+9,80 %)     MAGNUM 11.162 € (-0,66 %)     KERING 232.550 € (-1,50 %)     SAINT GOBAIN 76.460 € (-1,14 %)     MERSEN 31.020 € (+9,07 %)     PHILIPS KON 21.920 € (-5,31 %)     ABEO 8.440 € (+2,93 %)     SOITEC 113.100 € (+14,52 %)     HEINEKEN 64.920 € (-2,81 %)     ASM INTERNATIONAL 809.800 € (-0,27 %)     SWI CAPITAL 5.500 € (+2,61 %)     SAFRAN 268.800 € (-0,92 %)     VINCI 126.150 € (-1,87 %)     ALLFUNDS GROUP 8.810 € (+0,06 %)     ING GROEP N.V. 23.880 € (-0,56 %)     CSG 18.448 € (-3,46 %)     LVMH 448.450 € (-1,39 %)     SARTORIUS STED BIO 151.500 € (-3,38 %)     HAL TRUST 169.000 € (-0,82 %)     WITBE 2.300 € (+39,39 %)     VALEO 10.480 € (-0,66 %)     EXAIL TECHNOLOGIES 123.900 € (-0,72 %)     SCHNEIDER ELECTRIC 271.550 € (+0,28 %)     GROUPE SFPI 1.840 € (0,00 %)     AB SCIENCE 1.100 € (-6,62 %)     TELEPERFORMANCE 55.140 € (+1,92 %)     MON COURTIER ENERG 5.700 € (+3,64 %)     ARKEMA 61.350 € (-1,05 %)     VERALLIA 20.180 € (+0,50 %)     Vusion 128.500 € (-1,91 %)     EUROFINS SCIENT. 57.540 € (-3,71 %)     MERCIALYS 12.340 € (-1,75 %)     NN GROUP 73.620 € (-0,22 %)     VALNEVA 2.328 € (-3,56 %)     AHOLD DEL 39.790 € (-2,26 %)     LISI 61.500 € (+2,50 %)     STELLANTIS NV 6.640 € (-0,91 %)     SHELL PLC 37.830 € (-0,33 %)     BE SEMICONDUCTOR 239.400 € (+1,74 %)     DANONE 66.100 € (-1,93 %)     Coca-ColaEuropacif 81.300 € (-2,98 %)     MEDINCELL 24.820 € (+8,57 %)     TOTALENERGIES 78.230 € (-0,05 %)     HEXAOM 35.300 € (-0,56 %)     CAPGEMINI 102.700 € (+3,44 %)     CRCAM NORD CCI 27.730 € (-1,32 %)     AZERION 0.790 € (+2,60 %)     UMG 19.380 € (-0,08 %)     AKZO NOBEL 49.590 € (-1,33 %)     ARCELORMITTAL SA 48.970 € (-0,71 %)     STMICROELECTRONICS 44.720 € (+5,98 %)     DSM FIRMENICH AG 63.360 € (-0,31 %)     L'OREAL 365.600 € (-0,25 %)     E PANGO 0.247 € (+30,34 %)     CRCAM ATL.VEND.CCI 154.000 € (0,00 %)     CRCAM LANGUED CCI 88.500 € (+1,71 %)     AIRBUS 174.620 € (+5,13 %)  
News Réglementées
02/04/2026 11:05

Folly Launches First Pill-Strength Hair Health Gummy

EQS-News: Folly / Key word(s): Product Launch/Private Equity
Folly Launches First Pill-Strength Hair Health Gummy

02.04.2026 / 11:05 CET/CEST
The issuer is solely responsible for the content of this announcement.


On a Mission to Solve the Supplement Industry's Underdosing & Consistency Crisis

30+ clinically proven ingredients, 16x dosage compared to the average hair gummy; Biotech encapsulation-enabled breakthrough; Results reported in 30 days

LONDON, April 2, 2026 /PRNewswire/ -- Folly, the first biotech-powered hair supplement, today announced its global launch alongside a follow-on investment led by Khosla Ventures. The investment will accelerate global commercialization of the breakthrough encapsulation platform and expansion into new wellness categories.

Folly delivers 30+ clinically studied ingredients in a gummy form factor, at dosages previously associated only with pills and capsules, using Folly Microspheres, a proprietary microencapsulation system developed by parent company Genecis Bio. It is the first hair supplement to apply drug-delivery science to solve what the company calls "the supplement industry's consistency crisis."

Weak Formulas and Poor Consistency

Most hair supplements use similar buzzword ingredients: biotin, vitamins, pumpkin seed oil. On paper, many of them look comparable.

  1. Underdosing with gummies.
    Many gummies include ingredients at levels too low to meaningfully support hair biology, effectively becoming vitamin candy.
  2. Inconsistency with pills.
    Pill-based protocols often require taking 3-4 large pills daily. Over half of women report difficulty swallowing pills consistently.

Women cycle through products that look promising but either don't deliver meaningful dosing or are too cumbersome to stay on long enough to see results.

Folly delivers clinically studied ingredients at meaningful levels, not beauty-level doses designed for marketing appeal.

To make this possible in a gummy format, Folly developed a protective microsphere system – Folly Microspheres™ – that helps stabilize sensitive actives during production and digestion. This allows the gummy to maintain higher ingredient loading than typical hair gummies, without compromising taste or daily usability.

Luna Yu, Co-Founder and CEO:

"Folly was built to solve the supplement industry's delivery crisis: ensuring that clinically studied nutrients actually reach your follicles, not your stomach lining.

"I spent years working in pharmaceutical delivery science before realizing the supplement industry had never fully applied these principles. The same approaches that protect active ingredients in drug delivery can protect nutrients in a gummy. That is what Folly Microspheres do."

In a 300-person consumer perception study, women who used Folly daily for at least 30 days reported:

  • 84% saw improved hair health in 30 days
  • 81% noticed fuller-looking hair
  • 79% experienced less shedding

Folly launches in April 2026 in the U.S. and U.K., with expansion across Europe and Asia throughout 2026.

Visit: www.follynutrition.com / @FollyNutrition

Cision View original content:https://www.prnewswire.co.uk/news-releases/folly-launches-first-pill-strength-hair-health-gummy-302731595.html

rt.gif?NewsItemId=EN07813&Transmission_Id=202604020500PR_NEWS_EURO_ND__EN07813&DateId=20260402


02.04.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2303166  02.04.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière